Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AMOL RAJEEV H RAO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1689871154
CMS profile
76709
Location
FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,477.39

162 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,252.61 159
Education $124.78 2
Consulting Fee $100.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AMOL RAJEEV H RAO

NPI 1689871154 · CMS profile ID 76709

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AMOL RAJEEV H RAO, NPI 1689871154, CMS profile ID 76709, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 162 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1689871154?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

162 matching records · $3,477.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 162 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 162.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $21.0208/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764901 CMS
PFIZER INC. $10.1008/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673297567 CMS
CSL Behring $19.5508/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683842545 CMS
PFIZER INC. $13.5708/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673738973 CMS
Astellas Pharma US Inc $23.0408/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737109 CMS
TESARO, Inc. $36.0808/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675567559 CMS
Merck Sharp & Dohme Corporation $15.1508/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695690195 CMS
COMSORT, Inc $100.0008/01/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806019 CMS
PFIZER INC. $13.6607/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673774613 CMS
Merck Sharp & Dohme Corporation $19.0807/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695677947 CMS
Genentech USA, Inc. $20.8607/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681355841 CMS
TESARO, Inc. $27.5107/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675567557 CMS
Novartis Pharmaceuticals Corporation $39.3007/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764893 CMS
Janssen Pharmaceuticals, Inc $15.2107/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659224915 CMS
Pharmacyclics LLC, An AbbVie Company $23.1407/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665708655 CMS
E.R. Squibb & Sons, L.L.C. $3.8507/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371957 CMS
E.R. Squibb & Sons, L.L.C. $2.5507/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371959 CMS
Merck Sharp & Dohme Corporation $19.7107/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695662541 CMS
Merck Sharp & Dohme Corporation $15.7107/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695664077 CMS
Puma Biotechnology, Inc. $21.8207/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 706024867 CMS
Foundation Medicine, Inc. $24.8207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675551087 CMS
E.R. Squibb & Sons, L.L.C. $0.1607/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371947 CMS
E.R. Squibb & Sons, L.L.C. $12.3107/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371949 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.2307/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697398564 CMS
Octapharma USA, Inc. $20.4907/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692225589 CMS
Astellas Pharma US Inc $18.5907/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655737107 CMS
Novartis Pharmaceuticals Corporation $18.5106/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764865 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.3306/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 628421631 CMS
Takeda Pharmaceuticals U.S.A., Inc. $43.1206/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697395279 CMS
Clovis Oncology, Inc. $24.6806/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688688895 CMS
Regeneron Healthcare Solutions, Inc. $27.2306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673461549 CMS
Clovis Oncology, Inc. $13.5306/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688689149 CMS
E.R. Squibb & Sons, L.L.C. $0.1806/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371943 CMS
E.R. Squibb & Sons, L.L.C. $17.0406/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371945 CMS
PFIZER INC. $21.3406/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673635839 CMS
TerSera Therapeutics LLC $28.0606/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699772489 CMS
Incyte Corporation $23.1906/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666248657 CMS
Incyte Corporation $99.9506/14/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 666248661 CMS
TerSera Therapeutics LLC $28.0606/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699772487 CMS
AbbVie, Inc. $20.0006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647728029 CMS
Taiho Oncology, Inc. $13.2506/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 679423817 CMS
Amgen Inc. $21.5406/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662170359 CMS
TESARO, Inc. $17.6005/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 675567555 CMS
Exelixis Inc. $29.1705/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686550261 CMS
Celgene Corporation $24.4105/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673007881 CMS
Merck Sharp & Dohme Corporation $18.4305/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695542145 CMS
Novartis Pharmaceuticals Corporation $12.5305/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659764883 CMS
Genentech USA, Inc. $19.9605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681273119 CMS
AstraZeneca Pharmaceuticals LP $16.7105/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685503957 CMS
EISAI INC. $14.5705/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697008909 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,477.39 162
PY2020 $1,258.75 56
PY2021 $1,663.82 24
PY2022 $916.29 5
PY2023 $286.49 4
PY2024 $36,176.37 7
PY2025 $986.07 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,193,955.59 65
PY2024 Principal investigator $556,715.08 31
PY2023 Recipient $16.15 1
PY2023 Principal investigator $338,821.77 31
PY2022 Recipient $1,298.00 1
PY2022 Principal investigator $242,404.24 27
PY2021 Principal investigator $87,262.23 9
PY2020 Principal investigator $57,796.20 3
PY2019 Principal investigator $10,781.31 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

65 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $34,852.28 12/31/2025 Non-covered Recipient Entity
MemorialCare Orange Coast Medical Center
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative Breast Cancer TNBC Who Received No dispute reported 06/30/2026 1232923800
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $13,157.52 12/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753718
Principal investigator 1 Sumitomo Pharma America, Inc. $90.00 12/22/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES DBA MEMORIALCARE
RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) No dispute reported 06/30/2026 1176657716
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $2,534.32 12/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753720
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,370.74 12/03/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
a randomised,open label,phase III study of saruparib AZD5305 plus camizestrant compared with physicians choice CDK4 6 inhibitor plus endocrine therapy or plus camizestrant for the first line treatment of patients with BRCA1,BRCA2,or PALB2 mutations and hormone receptor positive, HER2 negative IHC 0,1+,2+ISH non-amplified advanced breast cancer evoPAR breast01 No dispute reported 06/30/2026 1185544641
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $9,808.75 12/01/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753682
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,247.86 11/14/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753716
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $106.40 10/31/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753726
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $750.00 10/31/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753728
Principal investigator 1 Daiichi Sankyo Inc. $7,573.06 10/30/2025 Non-covered Recipient Entity
Biomedical Research Alliance of New York LLC
DS8201-A-U305 No dispute reported 06/30/2026 1244555166
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,002.00 10/24/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic NSCLC With High PD-L1 Expression and Without Actionable Genomic Alterations (TROPION-Lung10) No dispute reported 06/30/2026 1185544643
Principal investigator 1 AstraZeneca Pharmaceuticals LP $54,800.22 10/22/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
a phase III,two arm,parallel,randomized,multi center,open label,global study to determine the efficacy of volrustomig,plus chemotherapy versus pembrolizumab plus chemotherapy for first line treatment of patients with metastatic non small cell lung cancer No dispute reported 06/30/2026 1185544657
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $11,521.29 10/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753714
Principal investigator 1 Daiichi Sankyo Inc. $370.00 10/02/2025 Non-covered Recipient Entity
Orange Coast Memorial Medical Center
DS8201-793 No dispute reported 06/30/2026 1223375617
Principal investigator 1 Daiichi Sankyo Inc. $945.00 10/02/2025 Non-covered Recipient Entity
Orange Coast Memorial Medical Center
DS8201-793 No dispute reported 06/30/2026 1223375619
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $23,000.00 09/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753722
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $18,706.45 09/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
ALI-1201 No dispute reported 06/30/2026 1251753724
Principal investigator 1 Exelixis Inc. $75.00 09/17/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381658
Principal investigator 1 Exelixis Inc. $75.00 09/17/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381660
Principal investigator 1 Mirati Therapeutics, Inc. $2,000.00 09/10/2025 Non-covered Recipient Entity
Memorialcare Health System
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutatio No dispute reported 06/30/2026 1236530935
Principal investigator 1 PFIZER INC. $1,125.00 09/09/2025 Non-covered Recipient Entity
Memorial Health Services
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228751049
Principal investigator 1 Exelixis Inc. $1,000.00 08/07/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381662
Principal investigator 1 Exelixis Inc. $3,200.00 08/07/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381664
Principal investigator 1 Exelixis Inc. $1,200.00 08/07/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381666
Principal investigator 1 AstraZeneca Pharmaceuticals LP $488,536.92 08/06/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544649
Principal investigator 1 Eli Lilly and Company $3,765.00 08/01/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
STUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) (BRUIN CLL-321) No dispute reported 06/30/2026 1187885720
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,000.00 07/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Randomised, Multicentre, Double-Blind, Phase III study will evaluate the safety and efficacy of AZD9833 next generation oral SERD in combination with CDK4 6 inhibitor palbociclib or abemaciclib versus aromatase inhibitor anastrozole or letrozole No dispute reported 06/30/2026 1185544639
Principal investigator 1 AstraZeneca Pharmaceuticals LP $32,759.65 07/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase III, Randomized,Open Label,Multi Center,Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma,Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy No dispute reported 06/30/2026 1185544655
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,502.00 07/02/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features, Following Complete Tumour Resection (TROPION Lung12) No dispute reported 06/30/2026 1185544647
Principal investigator 1 Daiichi Sankyo Inc. $325.56 06/24/2025 Non-covered Recipient Entity
MemorialCare Todd Cancer Institute
DS8201-A-U305 No dispute reported 06/30/2026 1223372184
Principal investigator 1 Exelixis Inc. $550.00 06/04/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381634
Principal investigator 1 Genentech, Inc. $10.00 06/04/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211623539
Principal investigator 1 Exelixis Inc. $5,357.30 05/28/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381648
Principal investigator 1 Exelixis Inc. $4,160.00 05/28/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381656
Principal investigator 1 Genentech, Inc. $3,450.00 05/27/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211623542
Principal investigator 1 PFIZER INC. $624.38 05/23/2025 Non-covered Recipient Entity
Memorial Health Services
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228764372
Principal investigator 1 Exelixis Inc. $3,491.80 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381632
Principal investigator 1 Exelixis Inc. $429.65 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381636
Principal investigator 1 Exelixis Inc. $1,050.40 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381640
Principal investigator 1 Exelixis Inc. $2,623.40 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381642
Principal investigator 1 Exelixis Inc. $2,493.40 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381644
Principal investigator 1 Exelixis Inc. $2,532.40 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381650
Principal investigator 1 Exelixis Inc. $2,730.00 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381652
Principal investigator 1 Exelixis Inc. $2,532.40 05/08/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381654
Principal investigator 1 AstraZeneca Pharmaceuticals LP $41,121.36 05/07/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 No dispute reported 06/30/2026 1185544635
Principal investigator 1 Genentech, Inc. $3,000.00 05/06/2025 Non-covered Recipient Entity
Long Beach Memorial Medical Center
Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC No dispute reported 06/30/2026 1211621228
Principal investigator 1 PFIZER INC. $8,949.25 05/01/2025 Non-covered Recipient Entity
Memorial Health Services
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228764861
Principal investigator 1 Exelixis Inc. $32.50 04/11/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381638
Principal investigator 1 Exelixis Inc. $550.00 04/11/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381646
Principal investigator 1 Daiichi Sankyo Inc. $3,160.50 03/31/2025 Non-covered Recipient Entity
MemorialCare Todd Cancer Institute
DS8201-A-U305 No dispute reported 06/30/2026 1223372182
Principal investigator 1 AstraZeneca UK Limited $9,783.34 03/25/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia No dispute reported 06/30/2026 1185544651
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,231.12 03/19/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II, lymph-node negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) No dispute reported 06/30/2026 1185544645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,668.03 03/19/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185544653
Principal investigator 1 AstraZeneca Pharmaceuticals LP $59,587.28 02/28/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab MEDI4736 and domvanalimab AB154 compared with durvalumab plus placebo in adults with locally advanced Stage III No dispute reported 06/30/2026 1185544637
Principal investigator 1 Exelixis Inc. $2,532.40 02/19/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381622
Principal investigator 1 Exelixis Inc. $2,623.40 02/19/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381624
Principal investigator 1 Exelixis Inc. $3,491.80 02/19/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381626
Principal investigator 1 Exelixis Inc. $1,050.40 02/19/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381628
Principal investigator 1 Exelixis Inc. $2,493.40 02/19/2025 Non-covered Recipient Entity
Memorial Health Services
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381630
Principal investigator 1 PFIZER INC. $1,500.00 02/14/2025 Non-covered Recipient Entity
Memorial Health Services
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228761015
Principal investigator 1 Exelixis Inc. $1,000.00 02/13/2025 Non-covered Recipient Entity
Orange Coast Medical Center
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222383022
Principal investigator 1 Exelixis Inc. $3,000.00 02/13/2025 Non-covered Recipient Entity
Orange Coast Medical Center
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222383024
Principal investigator 1 Exelixis Inc. $1,200.00 02/13/2025 Non-covered Recipient Entity
Orange Coast Medical Center
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222383026
Principal investigator 1 AstraZeneca Pharmaceuticals LP $108,995.66 01/29/2025 Non-covered Recipient Entity
MEMORIAL HEALTH SERVICES
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185544633
Principal investigator 1 PFIZER INC. $2,550.00 01/10/2025 Non-covered Recipient Entity
Memorial Health Services
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228801054